We are live on ! Find out more
PBM icon

Psyence Biomedical
PBM

6 hedge funds and large institutions have $625K invested in Psyence Biomedical in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more capital invested

Capital invested by funds: $273K → $625K (+$352K)

42.17% more ownership

Funds ownership: 11.64% → 53.81% (+42%)

25% less funds holding

Funds holding: 8 → 6 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
6
Holders Change
-2
Holders Change %
-25%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Parallel Advisors
California
+$1.22M
2
Bank of America
Bank of America
North Carolina
+$14.8K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$52.6K
2
Citadel Advisors
Citadel Advisors
Florida
-$45.2K
3
VF
Virtu Financial
New York
-$22K
4
UBS Group
UBS Group
Switzerland
-$9.99K
5
TSS
Two Sigma Securities
New York
-$7.76K

PBM Hedge Fund Activity: Q2 2025 in Review

6 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical (PBM) for Q2 2025, worth a combined $625K — up 129% from $273K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of PBM and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was Parallel Advisors, opening a new position worth an estimated $1.22M. The largest seller was Sabby Management, cutting an estimated $52.6K.

  • 6 institutional investors held Psyence Biomedical (PBM) as of Q2 2025, down from 8 in Q1 2025.
  • Funds reported $625K of Psyence Biomedical stock for Q2 2025, up 129% quarter-over-quarter.
  • 2 funds opened new Psyence Biomedical positions in Q2 2025 and 4 closed out, a net change of -2 holders.
  • The largest Psyence Biomedical buyer in Q2 2025 was Parallel Advisors, an estimated $1.22M added.
  • The largest Psyence Biomedical seller in Q2 2025 was Sabby Management, an estimated $52.6K sold.

Based on aggregated 13F filings for Q2 2025.